SCHEMBL25925819

SCHEMBL25925819

NS(=O)(=O)c1ccc2nsc(/N=N/c3ccc(O)c(/N=N/c4ccncc4)c3O)c2c1

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 3/20 0.42
KMT2A Q03164 3/20 0.42
CASP6 P55212 2/20 0.42
NPC1 O15118 1/20 0.42
RAB9A P51151 1/20 0.42
ATM Q13315 1/20 0.42
KLF5 Q13887 1/20 0.42
CDK1 P06493 7/20 0.41
CDK2 P24941 7/20 0.41
CCNA2 P20248 3/20 0.41
MAPT P10636 2/20 0.40
PTGS1 P23219 2/20 0.39
PTGS2 P35354 2/20 0.39
GLO1 Q04760 4/20 0.38
CA2 P00918 2/20 0.38
CA1 P00915 1/20 0.38
POLB P06746 1/20 0.36
IDO1 P14902 1/20 0.36
DNMT1 P26358 1/20 0.36
APEX1 P27695 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25925809 0.83 KMT2A (0.35) MEN1KMT2ACASP6NPC1RAB9A
SCHEMBL25925772 0.83 CYP1A2 (0.36) MEN1KMT2ACASP6NPC1RAB9A
SCHEMBL25927208 0.81 PTGS2 (0.36) MEN1KMT2ACASP6NPC1RAB9A
SCHEMBL25925792 0.80 MEN1 (0.33) MEN1KMT2ACASP6NPC1RAB9A
SCHEMBL18724507 0.78 CA2 (0.48) MEN1KMT2ACDK1CDK2CCNA2
SCHEMBL12795331 0.77 PTGS2 (0.61) CDK1CDK2CCNA2PTGS1PTGS2
SCHEMBL17514071 0.77 PTGS2 (0.61) CDK1CDK2CCNA2PTGS1PTGS2
SCHEMBL25925921 0.77 GLO1 (0.41) MEN1KMT2ACASP6NPC1RAB9A
SCHEMBL13025293 0.76 PTGS2 (0.50) MEN1KMT2ACDK1CDK2CCNA2
SCHEMBL25925818 0.74 MEN1 (0.42) MEN1KMT2ACASP6NPC1RAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230242523-A1 COMPOUND, TAUTOMER OF COMPOUND OR SALT OF COMPOUND OR TAUTOMER, METHOD FOR PRODUCING SAME, COLORING COMPOSITION, DYEING METHOD, AND DYED ARTICLE FUJIFILM CORPORATION (JP) 2023-08-03 US disclosed
US-20230242523-A1 COMPOUND, TAUTOMER OF COMPOUND OR SALT OF COMPOUND OR TAUTOMER, METHOD FOR PRODUCING SAME, COLORING COMPOSITION, DYEING METHOD, AND DYED ARTICLE FUJIFILM CORPORATION (JP) 2023-08-03 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230242523-A1 COMPOUND, TAUTOMER OF COMPOUND OR SALT OF COMPOUND OR TAUTOMER, METHOD FOR PRODUCING SAME, COLORING COMPOSITION, DYEING METHOD, AND DYED ARTICLE AR, MAPT, NR5A1 MEN1 67/4885KMT2A 1814/4885CASP6 4337/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.